Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Lung Neoplasms 8Small Cell Lung Carcinoma 6Neoplasms 4Neoplasm Metastasis 4Carcinoma, Hepatocellular 4Carcinoma 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Cholangiocarcinoma 3Triple Negative Breast Neoplasms 2Neoplasms by Site 2Neoplasms by Histologic Type 2Liver Neoplasms 2Gallbladder Neoplasms 2Endometrial Neoplasms 2Bile Duct Neoplasms 2Vaccinia 1Squamous Cell Carcinoma of Head and Neck 1Resectable Intrahepatic Cholangiocarcinoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Pathologic Complete Response 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Non-Small Cell Lung Cancer Metastatic 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Glandular and Epithelial 1Mouth Neoplasms 1Liver Diseases 1Laryngeal Neoplasms 1

Interventions

Specimen Handling 7Magnetic Resonance Spectroscopy 7Cisplatin 6pembrolizumab 5Carboplatin 5durvalumab 4Paclitaxel 4Cetuximab 4cemiplimab 3Radiation 3Platinum 3Pemetrexed 3Nivolumab 3Docetaxel 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3(225)Ac-DOTA-c(RGDyK) 3cabozantinib 2atezolizumab 2Radiotherapy 2Immunoglobulin G 2Disulfides 2ALT-803 2130-nm albumin-bound paclitaxel 2zipalertinib 1trifluridine tipiracil drug combination 1repotrectinib 1regorafenib 1poly ICLC 1ipatasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Carcinoma × durvalumab × 30 days × Clear all
NCT06463665 2026-06-04

VIRO-25

Genelux Corporation

Phase 2 Recruiting
142 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05063565 2026-06-01

ROWAN

Boston Scientific Corporation

Phase 2 Active not recruiting
100 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT05043090 2026-05-22

SAMETA

AstraZeneca

Phase 3 Active not recruiting
148 enrolled
Genitourinary

Carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡